Search

There seems to be an uncertainty about the periprocedural management of direct oral anticoagulants, which might be due to the different pharmacological and pharmacokinetic properties of the currently existing substances Apixaban, Dabigatran, Edoxaban and Rivaroxaban.Thus, using DOAC requires the calculation and evaluation of the individual riskfor bleeding and thromboembolism. Monitoring of the therapy is not common, but in some situations the concentration of the substance might be interesting. Depending on the substance different methods for monitoring exist. It is important to be aware of possible falsification of other coagulation markers. In case of severe bleeding PPSB will be necessary. So far Praxbind® (Idaru zumab) is the only available antidote. Flowever, as a result of current research, further therapy options concerning reversal for factor Xa inhibitors might be available in the near future. [ABSTRACT FROM AUTHOR]